SLC5A2 and Obesity: While cardiovascular outcomes studies with SGLT2 inhibitors have not assessed diabetic cardiomyopathy per se, preclinical studies have demonstrated that the SGLT2 inhibitor, empagliflozin, can attenuate diastolic dysfunction in obesity-induced cardiomyopathy (Sun et al., 2020).